Dr. Tremblay currently serves as the Chairman of the Board of Directors of AIM-HI. He is Chief Executive Officer of Blackbird Laboratories.
Prior to that he served as Chief Operating Officer of Scripps Research, as well as the Chief Operating Officer for its drug discovery division, the California Institute for Biological Research (Calibr), where he was responsible for developing and implementing corporate strategy for Scripps Research and Calibr, as well as the management of day-to-day operations. Tremblay works closely with the chief executive officer to create the long term strategic vision for the institute and advance new business development opportunities. Administrative functions reporting to the chief operating officer span business development, program management and clinical operations, legal and research services, information technology, and facilities, and encompass over 300 employees.
Doctorate in Chemistry, Columbia University
Tremblay played a key role in establishing Calibr in 2012, where he led a team of biologists in the discovery of new therapeutic agents for metabolic, cardiovascular and autoimmune diseases.
As Calibr grew to a 100+ employee drug discovery organization, he facilitated the launch of a number of strategic collaborations with major foundations and pharmaceutical companies, and was subsequently promoted to chief operating officer. When Calibr became an affiliate of Scripps Research in 2016, Tremblay took on the additional role of vice president for Business Development at the institute, before being named chief operating officer of the combined institutes in 2018. Tremblay earned his doctorate in Chemistry at Columbia University. Following postdoctoral work in the laboratory of Peter Schultz at Scripps Research, he led a group at the Genomics Institute of the Novartis Research Foundation before joining Calibr.